Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies
December 11th 2023Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.
Read More
Persistent ctDNA Correlates With Disease Recurrence in HR+/HER2– Early Breast Cancer
December 6th 2023Detection of circulating tumor DNA with the Signatera assay was associated with disease recurrence in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer at 24 months post-randomization to treatment with adjuvant abemaciclib and endocrine therapy.
Read More
Acalabrutinib Plus BR Leads to High CR Rates in Treatment-Naive, Relapsed/Refractory MCL
June 9th 2023The addition of acalabrutinib to bendamustine and rituximab demonstrated potent and durable responses despite a high incidence of grade 3/4 adverse effects in patients with previously untreated and relapsed/refractory mantle cell lymphoma.
Read More
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Chemo Produces Responses in Advanced NSCLC
June 6th 2023Combination treatment consisting of datopotamab deruxtecan and pembrolizumab with or without platinum-based chemotherapy generated responses as first- or second-line treatment for patients with advanced or metastatic non–small cell lung cancer.
Read More
Talazoparib/Enzalutamide Combo Significantly Improves rPFS in HRR Gene–Altered mCRPC
June 4th 2023The combination of talazoparib and enzalutamide resulted in a statistically significant and clinically meaningful improvement in radiographic progression-free survival when used as a first-line therapy for patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.
Read More
IBI351 Demonstrates Early Antitumor Activity and Tolerability in KRAS G12C+ Advanced NSCLC
April 18th 2023The recommended phase 2 dose of IBI351 monotherapy had favorable safety and encouraging efficacy signals when administered to patients with advanced KRAS G12C–mutated non–small cell lung cancer, according to updated data from a phase 1 dose-escalation study.
Read More
Dostarlimab Plus Chemotherapy Elicits PFS Benefit in Recurrent Endometrial Cancer
March 28th 2023Dostarlimab plus standard-of-care chemotherapy generated a significant improvement in progression-free survival vs chemotherapy alone for patients with recurrent endometrial cancer, including those with mismatch repair–deficient, microsatellite instability–high tumors.
Read More
Niraparib Maintenance Does Not Produce Long-term OS Benefit in Recurrent Ovarian Cancer
March 27th 2023Maintenance niraparib did not produce a statistically significant overall survival benefit compared with placebo in patients with recurrent ovarian cancer, according to data from an updated exploratory OS analysis of the phase 3 ENGOT-OV16/NOVA study.
Read More
High initial complete remission with or without platelet recovery, as well as an improvement in durable complete remission was achieved with the use of Iomab-B-based conditioning prior to allogeneic hematopoietic cell transplantation compared with conventional care in older patients with relapsed/refractory acute myeloid leukemia.
Read More
bTACE Plus Lenvatinib and MWA Produces Responses, Tolerability in HCC
January 20th 2023Blank-microsphere transarterial chemoembolization plus low-dose lenvatinib and sequential microwave ablation elicited responses and a tolerable safety profile in patients with large hepatocellular carcinoma.
Read More
Addition of Neoadjuvant Pembrolizumab Improves EFS in Resectable Melanoma
September 11th 2022Compared with adjuvant pembrolizumab alone, the addition of neoadjuvant pembrolizumab significantly improved event-free survival outcomes for patients with stage III-IV melanoma with a hazard ratio of 0.58.
Read More
Frontline Tislelizumab Demonstrates Noninferior OS Vs Sorafenib in Unresectable HCC
September 11th 2022Tislelizumab monotherapy provided a clinically meaningful overall survival benefit that was noninferior to sorafenib and showcased a favorable toxicity profile when used as a frontline treatment for patients with unresectable hepatocellular carcinoma.
Read More
Durvalumab/Tremelimumab Combo Provides OS Benefit in First-Line Metastatic NSCLC
August 6th 2022The combination use of first-line durvalumab plus tremelimumab for the treatment of patients with metastatic non–small cell lung cancer improved overall survival compared with standard-of-care chemotherapy.
Read More
Cilta-Cel Demonstrates Durable Responses at 2 Years Across Multiple Subgroups in R/R Myeloma
December 14th 2021Data from a longer follow-up analysis of the phase 1/2 CARTITUDE-1 trial demonstrated that all evaluated subgroups of patients with relapsed/refractory multiple myeloma maintained durable responses with ciltacabtagene autoleucel.
Read More
Additional Research Efforts Required to Establish New Therapeutic Options for Low-Risk MDS
September 8th 2021Because standardized treatment approaches have not been established for patients with low-risk myelodysplastic syndromes and limited options are available to those with erythropoietin failure, the need for varied clinical trials is underscored.
Read More
Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL
June 12th 2021In the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large b-cell lymphoma in the outpatient setting who are receiving the CAR T-cell therapies prior to failure on 2 prior lines of therapy.
Read More
Regorafenib/Pembrolizumab Combination Yields Encouraging Results in Advanced HCC
June 10th 2021The combination of regorafenib plus pembrolizumab in the first-line setting for patients with advanced hepatocellular carcinoma showed encouraging anti-tumor activity with a disease control rate of 91%, and did not display any new safety signals.
Read More
Tucatinib Concentrations in CSF Demonstrated in HER2+ Metastatic Breast Cancer
June 4th 2021Evidence of tucatinib and its predominant metabolite, ONT-993, were detectable in the cerebrospinal fluid of patients with leptomeningeal metastasis HER2+ positive breast cancer marking a first for tucatinib distribution into the CSF seen in this patient population.
Read More